InDevR
Latest round
- Series A
Last raised
- Sep 2019
Total raised
- $7M
Investors
- 1
About InDevR
InDevR, Inc. develops advanced analytical solutions for vaccine testing, focusing on optimizing development processes through their innovative VaxArray Platform for various vaccine types. Founded in 2003 and headquartered in Boulder, US, InDevR, Inc. specializes in analytical solutions for the biopharmaceutical sector. The company has not undergone significant strategic pivots and operates independently without known subsidiaries. The founding team, including CEO Ali Asghar and Kathy Rowlen, brings a wealth of industry experience. In January 2026, SSI Diagnostica A/S, a portfolio company of Adelis Equity, acquired InDevR, Inc. from Adjuvant Capital. Financial terms were not disclosed. InDevR specializes in providing innovative analytical solutions for vaccine testing, primarily through their flagship VaxArray Platform. This platform utilizes multiplex assay technology to deliver rapid and reliable analytical results, accommodating various assays in a single multiplex array. It serves multiple vaccine types, including mRNA, polysaccharide, conjugate, and viral vector vaccines, expediting development, optimization, and production processes. InDevR's offerings are designed for diverse stages of vaccine development, from research and development to clinical trials and product release testing.InDevR generates revenue through direct business-to-business transactions with clients, typically in the biopharmaceutical and vaccine development sectors. The company offers both off-the-shelf and custom analytical solutions, allowing for tailored service options that meet specific client requirements. Transactions are structured around the sale of VaxArray assays and related services, with clients purchasing kits designed for specific vaccine testing needs. Due to the customized nature of its offerings, pricing plans are structured according to the complexity and scale of the services provided, ensuring clients receive efficient solutions tailored to their unique challenges. The firm’s revenue model reflects a commitment to providing high-quality, pre-validated assays that facilitate faster vaccine development timelines, particularly in response to evolving public health needs. Upcoming product developments are focused on new multiplex assays that will be released in the next 18 months, aiming to facilitate broader vaccine testing applications. The company is targeting expansion into emerging markets in Asia and South America, capitalizing on the growing demand for advanced vaccine testing solutions in these regions.
Who invested in InDevR
1 investor across 1 round
See all investors in InDevR
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 10, 2019
Amount
$7M
Investors
Questions about InDevR
Who invested in InDevR?
InDevR has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has InDevR raised?
InDevR has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did InDevR last raise money?
InDevR's most recent round on record is a Series A, in Sep 2019.
What does InDevR do?
InDevR is a biotechnology company.
Where is InDevR headquartered?
InDevR is headquartered in Boulder, US.
Which VCs invest in companies like InDevR?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at InDevR's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like InDevR? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.